High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells

Circulation

Volumn 95, Issue 8, 1997, Pages 2115-2121

  Upchurch, Gilbert R ^a,b   Welch, George N ^a   Freedman, Jane E ^a   Fabian, Attila J ^a   Pigazzi, Alessio ^a   Scribner, Anne M ^a   Alpert, Caroline S ^a   Keaney Jr , John F ^a   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

anticoagulants; endothelium; endothelium derived factors; heparin; thrombosis

Indexed keywords

DEXTRAN SULFATE; HEPARIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ARTERY ENDOTHELIUM; ARTICLE; CATTLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM CELL; HEPARINIZATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0343052853     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.8.2115     Document Type: Article

References (50)

1. Howell WH. Heparin, an anticoagulant: preliminary communication. Am J Physiol. 1922;63:434-435.
2. Best CH, Cowan C, MacLean DL. Heparin and the formation of white thrombi. J Physiol. 1938;92:20-30.
3. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest. 1989;84:18-27.
4. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci U S A. 1988;85: 3184-3188.
5. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood. 1991;77:1006-1012.
6. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665.
7. Heras M, Chesebro JH, Webster MW, Mruk JS, Grill DE, Fuster V. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. Arterioscler Thromb. 1992;12:250-255.
8. Fareed J, Walenga JM, Hoppensteadt DA, Messmore HL. Studies on the profibrinolytic actions of heparin and its fractions. Semin Thromb Hemost. 1985;11:199-207.
9. Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res. 1983;30:219-224.
10. Upchurch GR Jr, Valeri CR, Khuri SF, Rohrer MJ, Welch GN, MacGregor H, Ragno H, Francis S, Rodino LJ, Michelson AD, Loscalzo J. The effect of heparin on fibrinolytic activity and platelet function in vivo. Am J Physiol (Heart Circ Physiol). 1996;271-H528-H534.
11. Landolfi R, De Candia E, Rocca B, Ciabattoni G, Antinori A, Masetti R, Patrono C. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis in vivo. Thromb Haemost. 1994;72:942-946.
12. Noris P, Bertolino G, Previtali M, Ferrario M, Balduini CL. Heparin infusion facilitates ex vivo spontaneous platelet aggregation in patients with acute myocardial infarction who have undergone thrombolytic therapy. Haemostasis. 1993;23:185-191.
13. Chen JH, Karlberg KE, Sylven C. Heparin and low molecular weight heparin but not hirudin stimulate platelet aggregation in whole blood from acetylsalicylic acid treated healthy volunteers. Thromb Res. 1991;63:319-329.
14. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:192-194.
15. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
16. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84: 9265-9269.
17. Myers RP, Minor RL Jr, Guerra R Jr, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature. 1990;345:161-163.
18. Randomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987;92:181-187.
19. Akata T, Kodama K, Takahashi S. Effects of heparin on the vasodilator action of protamine in the rabbit mesenteric artery. Br J Pharmacol. 1993;109:1247-1253.
20. Light JT Jr, Bellan JA, Roberts MP, Force SD, Chen IL, Kerstein MD, Kadowitz PJ, McNamara DB. Heparin treatment enhancesthe recovery of neoendothelial acetylcholine-induced vascular relaxation after balloon catheter injury in the rabbit aorta. Circulation. 1993;88(suppl II):II-413-II-419.
21. Chinellato A, Ragazzi E, Pandolfo L, Froldi G, Bevilacqua C, Prosdocimi M, Caparrotta L, Fassina G. Protective role of heparin on in vitro functional aortic response in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis. 1992;92:17-24.
22. Schwartz SM. Selection and characterization of bovine aortic endothelial cells. In Vitro. 1978;14:966-980.
23. Haudenschild CC, Zahniser D, Folkman J, Klagsburn M. Human vascular endothelial cells in culture: lack of response to serum growth factors. Exp Cell Res. 1976;98:175-183.
24. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52: 2745-2756.
25. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973;52:2757-2764.
26. Folkman J, Klagsburn M. Angiogenic factors. Science. 1987;235: 442-447.
27. Davies PF, Truskey GA, Warren HB, O'Connor SE, Eisenhaure BH. Metabolic cooperation between vascular endothelial cells and smooth muscle cells in co-culture: changes in low density lipoprotein metabolism. J Cell Biol. 1985;101:871-879.
28. Freedman JE, Fabian A, Loscalzo J. Impaired EDRF production by endothelial cells exposed to fibrin monomer and FDP. Am J Physiol. 1995;268:C520-C526.
29. Stamler J, Mendelsohn ME, Amarante D, Smick D, Andon N, Davies PF, Cooke JP, Loscalzo J. N-Acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res. 1989;65:789-795.
30. Pai TG, Payne WJ, LeGall J. Use of a chemiluminescence detector for quantitation of nitric oxide produced in assays of denitrifying enzymes. Anal Biochem. 1987;166:150-157.
31. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A. 1992;89:7674-7677.
32. Welch GN, Upchurch GR Jr, Loscalzo J. S-Nitrosothiol detection. Methods Enzymol. 1996;268:293-298.
33. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial cell nitric oxide synthase: molecular cloning and characterization of a distinctive constitutive enzyme isoform. Proc Natl Acad Sci U S A. 1992;89:6348-6352.
34. Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA, MacGregor H, Doursounian M, Zolkewitz BS. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg. 1995;60:1008-1014.
35. Donaldson MC, Mannick JA, Whittemore AD. Causes of primary graft failure after in situ saphenous vein bypass grafting. J Vasc Surg 1992;15:113-118.
36. Holmes DR, Schwartz RS, Webster MW. Coronary restenosis: what have we learned from angiography? J Am Coll Cardiol. 1991; 17:14B-22B.
37. Mendelsohn ME, O'Neill S, George D, Loscalzo J. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem. 1990;265:19028-19034.
38. Kessler DA, Langer RS, Pless NA, Folkman J. Mast cells and tumor angiogenesis. Int J Cancer. 1976;18:703-709.
39. Rosenburg RD, Fritze LMS, Castellot JJ Jr, Karnovsky MJ. Heparin-like molecules as regulators of atherogenesis. Nouv Rev Fr Hematol. 1984;26:255-260.
40. Hiebert LM, Wice SM, McDuffie NM, Jaques LB. The heparin target organ: the endothelium: studies in a rat model. Q J Med. 1993;86:341-348.
41. Hiebert LM, Liu J. Heparin protects cultured endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis. 1990;83:47-51.
42. Hiebert LM, Liu J. The protective action of polyelectrolytes on endothelium. Semin Thromb Hemost. 1991;17(suppl 1):42-46.
43. Robinson-White A, Baylin SB, Olivecrona T, Beaven MA. Binding of diamine oxidase activity to rat and guinea pig microvascular endothelial cells: comparison with lipoprotein lipase binding. J Clin Invest. 1985;76:93-100.
44. Karlsson K, Marklund SL. Heparin-induced release of extracellular superoxide dismutase to human blood plasma. Biochem J. 1987;242: 55-59.
45. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454-456.
46. Rubanyi GM, Vanhoutte P. Superoxide anions and hypoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 1986;250: H822-H827.
47. Boitano S, Dirksen ER, Sanderson MJ. Intercellular propagation of calcium waves mediated by inositol phosphate. Science. 1992;258: 292-295.
48. Dinerman JL, Lowenstein CJ, Snyder SH. Molecular mechanisms of nitric oxide regulation: potential relevance to cardiovascular disease. Circ Res. 1993;73:217-222.
49. Imai T, Hirata Y, Marumo F. Heparin inhibits endothelin-1 and proto-oncogene c-fos gene expression in cultured bovine endothelial cells. J Cardiovasc Pharmacol. 1993;22:S49-S52.
50. Yokokawa K, Tahara H, Kohno M, Mandal AK, Yanagisawa M, Takeda T. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest. 1993;92:2080-2085.